Busting the myths of pharma RFID
by A.T. Kearney Inc.
Companies are gearing up to take advantage of radio frequency identification (RFID) technology, which has the potential to combat counterfeiting, reduce patient safety risks, provide brand protection and improve operational efficiency. Questions of cost, implementation and maintenance may seem daunting, but the potential benefits offer more than enough incentives to offset the questions. Leading players including Pfizer Inc., GlaxoSmithKline Inc. and Purdue Pharma are beginning to tag their highest profile products and have plans to track the rest. As with any large-scale, fast-moving initiative, information about RFID is mixed with myths. In this white paper, A.T. Kearney Inc. debunks five of those myths.
| Published: | 2005 |
| Format: | |
| Length: | 14 pages |
| Type: | White paper |
| Language: | English |
.
SPONSORED REPORTS
